Phase III, double-blind, randomized, placebo-controlled trial of FavID (Id/KLH) [mitumprotimut T] and GM-CSF following CHOP/rituximab [cyclophosphamide + doxorubicin + vincristine + prednisone + rituximab] as first-line therapy in subjects with high-intermediate and high-risk diffuse large B-cell lymphoma

Trial Profile

Phase III, double-blind, randomized, placebo-controlled trial of FavID (Id/KLH) [mitumprotimut T] and GM-CSF following CHOP/rituximab [cyclophosphamide + doxorubicin + vincristine + prednisone + rituximab] as first-line therapy in subjects with high-intermediate and high-risk diffuse large B-cell lymphoma

Suspended
Phase of Trial: Phase III

Latest Information Update: 04 Jun 2007

At a glance

  • Drugs Mitumprotimut T (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors MMRGlobal
  • Most Recent Events

    • 04 Jun 2007 Status changed from recruiting to suspended.
    • 06 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top